Saturday, March 15, 2025 | 04:07 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

PSAI segment decline pulls down Dr Reddy's Q1 show

Earnings were driven by one-off gains

drugs, medicines, USFDA
Premium

Representative Image

Ujjval Jauhari
Dr Reddy’s below than expected performance for the June quarter was led by a temporary disruption in the manufacturing of the active ingredient. Pharmaceutical services and Active Ingredients (PSAI) segment reported a 10 per cent decline in sales on a year-on-year basis and 33 per cent sequentially. The management, however, said that segments sales would normalize in the September quarter.

Global Generics sales grew 8 per cent year-on-year and 9 per cent sequentially. India and

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in